Dr. Koenig is a Professor of Medicine and Cardiology at the University of Ulm Medical School, Ulm, Germany. He graduated from the University of Munich and received his MD from the University of Heidelberg and the PhD from the University of Ulm. He is Board certified in internal medicine, cardiology, and in intensive care medicine with special interest in invasive and interventional cardiology. He also trained in cardiovascular disease epidemiology and is a former Director of the WHO-MONICA Augsburg Myocardial Infarction Register. Previous Hospital Appointments include: Director of the Emergency Room 1995-2000; Deputy Director, Departments of Internal Medicine 1995-2000; Director of the Intensive Care Unit 2003-2004, and Director of Cardiovascular Laboratories 2004-2005. At present he serves as a Consultant in Cardiology, and is the Director of the Preventive Cardiology Program and the Clinical Trial Unit (CTU) at the Department of Internal Medicine II – Cardiology of the University of Ulm Medical Center.
Dr. Koenig`s research interests involve the molecular basis of atherothrombogenesis including genetics with particular interest in the interrelations between hemostasis, inflammation, and atherothrombotic complications / type 2 diabetes, the metabolic syndrome, the clinical pharmacology of cardiovascular active compounds, and the clinical epidemiology of cardiovascular disorders, focusing on the identification and evaluation of new biomarkers for cardiometabolic diseases.
Dr. Koenig has published more than 600 research papers and reviews in journals including Nature, Nature Genetics, New England Journal of Medicine, JAMA, The Lancet, Circulation, Diabetes, Diabetes Care, British Medical Journal, Arteriosclerosis, Thrombosis & Vascular Biology, Atherosclerosis, and the European Heart Journal, and is the author/coauthor of more than 400 oral or poster presentations at various International Scientific Meetings. He has an H-Index of 60.
He is a member of the Editorial Board of Clinical Chemistry and was Associate Editor of Atherosclerosis (2008 – 2014). In 1999, he served as a Visiting Professor at the Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia, USA. Presently he serves on the Steering Committee of various large international randomized clinical trials testing innovative targets in cardiovascular medicine.